DK1349856T3 - Isoindolin-1-on-glucokinase-aktivatorer - Google Patents
Isoindolin-1-on-glucokinase-aktivatorerInfo
- Publication number
- DK1349856T3 DK1349856T3 DK01986857T DK01986857T DK1349856T3 DK 1349856 T3 DK1349856 T3 DK 1349856T3 DK 01986857 T DK01986857 T DK 01986857T DK 01986857 T DK01986857 T DK 01986857T DK 1349856 T3 DK1349856 T3 DK 1349856T3
- Authority
- DK
- Denmark
- Prior art keywords
- isoindolin
- glucokinase activators
- glucokinase
- activators
- diabetes
- Prior art date
Links
- 239000012190 activator Substances 0.000 title abstract 2
- 102000030595 Glucokinase Human genes 0.000 abstract 1
- 108010021582 Glucokinase Proteins 0.000 abstract 1
- -1 Isoindolin-1-one-substituted propionamide Chemical class 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25527300P | 2000-12-13 | 2000-12-13 | |
US31871501P | 2001-09-13 | 2001-09-13 | |
PCT/EP2001/014404 WO2002048106A2 (en) | 2000-12-13 | 2001-12-07 | Isoindolin-1-one glucokinase activators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1349856T3 true DK1349856T3 (da) | 2005-10-17 |
Family
ID=26944583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01986857T DK1349856T3 (da) | 2000-12-13 | 2001-12-07 | Isoindolin-1-on-glucokinase-aktivatorer |
Country Status (36)
Country | Link |
---|---|
US (1) | US6482951B2 (hu) |
EP (1) | EP1349856B1 (hu) |
JP (1) | JP4021766B2 (hu) |
KR (1) | KR100520651B1 (hu) |
CN (1) | CN1247574C (hu) |
AT (1) | ATE297922T1 (hu) |
AU (2) | AU3841502A (hu) |
BG (1) | BG107903A (hu) |
BR (1) | BR0116169A (hu) |
CA (1) | CA2430579C (hu) |
CY (1) | CY1105587T1 (hu) |
CZ (1) | CZ20031882A3 (hu) |
DE (1) | DE60111570T2 (hu) |
DK (1) | DK1349856T3 (hu) |
EG (1) | EG24358A (hu) |
ES (1) | ES2243578T3 (hu) |
HK (1) | HK1063314A1 (hu) |
HR (1) | HRP20030450B1 (hu) |
HU (1) | HUP0400587A3 (hu) |
IL (2) | IL156264A0 (hu) |
MA (1) | MA26973A1 (hu) |
MX (1) | MXPA03005170A (hu) |
MY (1) | MY136741A (hu) |
NO (1) | NO325810B1 (hu) |
NZ (1) | NZ526236A (hu) |
PA (1) | PA8534601A1 (hu) |
PE (1) | PE20020593A1 (hu) |
PL (1) | PL366006A1 (hu) |
PT (1) | PT1349856E (hu) |
RS (1) | RS50933B (hu) |
RU (1) | RU2249590C2 (hu) |
SI (1) | SI1349856T1 (hu) |
SK (1) | SK8732003A3 (hu) |
TW (1) | TWI294876B (hu) |
UY (1) | UY27069A1 (hu) |
WO (1) | WO2002048106A2 (hu) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
WO2004050645A1 (en) | 2002-10-03 | 2004-06-17 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
PT1549638E (pt) | 2002-10-03 | 2007-12-11 | Hoffmann La Roche | Indole-3-cabboxamidas como activantes da glucoquinase |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
US7262196B2 (en) * | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
CA2560689C (en) | 2004-04-02 | 2011-03-01 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes |
CA2561157A1 (en) * | 2004-04-02 | 2005-10-13 | Novartis Ag | Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
KR20080040046A (ko) * | 2005-08-31 | 2008-05-07 | 아스텔라스세이야쿠 가부시키가이샤 | 티아졸 유도체 |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
KR20080048504A (ko) | 2005-09-29 | 2008-06-02 | 사노피-아벤티스 | 페닐- 및 피리디닐-1,2,4-옥사디아졸론 유도체, 이의제조방법 및 약제로서의 이의 용도 |
GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
CN101316837A (zh) * | 2005-11-01 | 2008-12-03 | 詹森药业有限公司 | 作为葡萄糖激酶变构调节剂的取代的吡咯酮类 |
JP2009513704A (ja) * | 2005-11-01 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン |
CA2628259A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
EP1960386A2 (en) * | 2005-11-01 | 2008-08-27 | Janssen Pharmaceutica N.V. | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase |
WO2007051845A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Ltd | Tricyclo substituted amides |
EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
WO2007143434A2 (en) * | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
WO2008074694A1 (en) * | 2006-12-20 | 2008-06-26 | F. Hoffmann-La Roche Ag | Crystallization of glucokinase activators |
TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
EP2116533B1 (en) | 2007-03-07 | 2013-07-10 | Kyorin Pharmaceutical Co., Ltd. | Glucokinase activator |
WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
CL2009000004A1 (es) * | 2008-01-15 | 2010-02-19 | Lilly Co Eli | Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia. |
JP5623914B2 (ja) * | 2008-01-24 | 2014-11-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 糖尿病を処置するためのβアミノ酸誘導体 |
KR101608259B1 (ko) * | 2008-04-28 | 2016-04-01 | 교린 세이야꾸 가부시키 가이샤 | 시클로펜틸아크릴산아미드 유도체 |
KR20110018366A (ko) * | 2008-05-16 | 2011-02-23 | 다케다 샌디에고, 인코포레이티드 | 글루코키나아제 활성제 |
AU2009290474A1 (en) * | 2008-09-11 | 2010-03-18 | Pfizer Inc. | Heteroaryls amide derivatives and their use as glucokinase activators |
AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
US8470866B2 (en) * | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
DK3004076T3 (da) * | 2013-05-27 | 2020-01-02 | Hoffmann La Roche | Nye 3,4-dihydro-2h-isoquinolin-1-on- og 2,3-dihydro-isoindol-1-on-forbindelser |
EA201592263A1 (ru) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3883930A1 (en) | 2018-11-20 | 2021-09-29 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
CN116283717A (zh) * | 2023-01-06 | 2023-06-23 | 暨南大学 | 一种藁本内酯衍生物及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2687147A1 (fr) * | 1992-02-11 | 1993-08-13 | Union Pharma Scient Appl | Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
CN1151140C (zh) | 1999-03-29 | 2004-05-26 | 霍夫曼-拉罗奇有限公司 | 葡糖激酶活化剂 |
WO2001083478A2 (en) | 2000-05-03 | 2001-11-08 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
DE60106599T2 (de) | 2000-05-08 | 2006-02-09 | F. Hoffmann-La Roche Ag | Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren |
-
2001
- 2001-12-06 US US10/010,978 patent/US6482951B2/en not_active Expired - Fee Related
- 2001-12-07 PL PL01366006A patent/PL366006A1/xx unknown
- 2001-12-07 RS YUP-477/03A patent/RS50933B/sr unknown
- 2001-12-07 EP EP01986857A patent/EP1349856B1/en not_active Expired - Lifetime
- 2001-12-07 RU RU2003120512/04A patent/RU2249590C2/ru not_active IP Right Cessation
- 2001-12-07 SK SK873-2003A patent/SK8732003A3/sk unknown
- 2001-12-07 AU AU3841502A patent/AU3841502A/xx active Pending
- 2001-12-07 BR BR0116169-5A patent/BR0116169A/pt not_active Application Discontinuation
- 2001-12-07 CN CNB018206107A patent/CN1247574C/zh not_active Expired - Fee Related
- 2001-12-07 AU AU2002238415A patent/AU2002238415B2/en not_active Ceased
- 2001-12-07 SI SI200130381T patent/SI1349856T1/xx unknown
- 2001-12-07 MX MXPA03005170A patent/MXPA03005170A/es active IP Right Grant
- 2001-12-07 AT AT01986857T patent/ATE297922T1/de active
- 2001-12-07 DE DE60111570T patent/DE60111570T2/de not_active Expired - Lifetime
- 2001-12-07 NZ NZ526236A patent/NZ526236A/xx unknown
- 2001-12-07 PT PT01986857T patent/PT1349856E/pt unknown
- 2001-12-07 WO PCT/EP2001/014404 patent/WO2002048106A2/en active IP Right Grant
- 2001-12-07 CZ CZ20031882A patent/CZ20031882A3/cs unknown
- 2001-12-07 CA CA2430579A patent/CA2430579C/en not_active Expired - Fee Related
- 2001-12-07 HU HU0400587A patent/HUP0400587A3/hu unknown
- 2001-12-07 ES ES01986857T patent/ES2243578T3/es not_active Expired - Lifetime
- 2001-12-07 KR KR10-2003-7007869A patent/KR100520651B1/ko not_active IP Right Cessation
- 2001-12-07 JP JP2002549637A patent/JP4021766B2/ja not_active Expired - Fee Related
- 2001-12-07 IL IL15626401A patent/IL156264A0/xx unknown
- 2001-12-07 DK DK01986857T patent/DK1349856T3/da active
- 2001-12-10 EG EG20011316A patent/EG24358A/xx active
- 2001-12-10 PA PA20018534601A patent/PA8534601A1/es unknown
- 2001-12-10 TW TW090130510A patent/TWI294876B/zh not_active IP Right Cessation
- 2001-12-11 PE PE2001001234A patent/PE20020593A1/es not_active Application Discontinuation
- 2001-12-11 MY MYPI20015613A patent/MY136741A/en unknown
- 2001-12-12 UY UY27069A patent/UY27069A1/es not_active Application Discontinuation
-
2003
- 2003-06-02 IL IL156264A patent/IL156264A/en not_active IP Right Cessation
- 2003-06-04 HR HR20030450A patent/HRP20030450B1/xx not_active IP Right Cessation
- 2003-06-12 NO NO20032674A patent/NO325810B1/no not_active IP Right Cessation
- 2003-06-12 MA MA27197A patent/MA26973A1/fr unknown
- 2003-06-13 BG BG107903A patent/BG107903A/bg unknown
-
2004
- 2004-08-11 HK HK04106031A patent/HK1063314A1/xx not_active IP Right Cessation
-
2005
- 2005-09-15 CY CY20051101133T patent/CY1105587T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1349856T3 (da) | Isoindolin-1-on-glucokinase-aktivatorer | |
MY135222A (en) | Substituted phenylacetamides and their use as glucokinase activators | |
PT1282611E (pt) | Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase | |
MY180762A (en) | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators. | |
PT1311504E (pt) | Tetrazolil-fenil-acetamidas activadoras da glucoquinase | |
MY136764A (en) | Indole-3-carboxamides as glucokinase (gk) activators | |
MXPA05008406A (es) | Compuestos de amida tri(ciclo)-sustituida. | |
DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
DE602004026113D1 (de) | Glp-1-verbindungen | |
DE60134251D1 (de) | Verwendung von glp-2-peptiden | |
CY1109972T1 (el) | Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας | |
YU68002A (sh) | Modifikovani faktor viii | |
DK1196172T3 (da) | (S,S)-reboxetin til behandling af kronisk smerte | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
ATE320457T1 (de) | Polyurethanlösungen mit alkoxysilanstruktureinheiten | |
DE60229414D1 (de) | Verwendung von aplidine in der behandlung von pankreaskrebs | |
BR0314139A (pt) | Derivados de 1,4-pirazina substituìdos | |
WO2002024181A3 (en) | The use of melatonin for induction of general anesthesia | |
ATE305796T1 (de) | Präparationen von vitamin e in kombination mit afamin | |
JO2238B1 (en) | Glycine stimulants iswindline 1- on | |
DE10342518A1 (de) | Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität | |
MXPA04000418A (es) | Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas. | |
MX2007004040A (es) | Uso para alfa-simpatomimeticos con estructura de 2-imidazolina. | |
MXPA04003673A (es) | Uso de aplidina para el tratamiento de cancer pancreatico. | |
UA70017A (en) | Method for conservative treatment of chronic tonsillitis in adults |